

| OMB APPROVAL                                 |           |
|--|-----------|
| OMB Number:                                  | 3235-0287 |
| Estimated average burden hours per response: | 0.5       |

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

|   |   |  |
|---|---|--|
| 1. Name and Address of Reporting Person*<br><u>Robb Gary Charles</u><br><br>(Last) (First) (Middle)<br>C/O CORCEPT THERAPEUTICS INCORPORATED<br>149 COMMONWEALTH DRIVE<br><br>(Street)<br>MENLO PARK CA 94025<br><br>(City) (State) (Zip) | 2. Issuer Name and Ticker or Trading Symbol<br><u>CORCEPT THERAPEUTICS INC [CORT]</u> | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)<br>Director _____ 10% Owner _____<br>Officer (give title below) _____ Other (specify below) _____<br><b>Chief Business Officer</b> |
|   | 3. Date of Earliest Transaction (Month/Day/Year)<br><u>12/04/2023</u>                 |  |
|   | 4. If Amendment, Date of Original Filed (Month/Day/Year)                              |  |

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) |   | 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) |            |           | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|------------|-----------|---|--|---|
|                                 |                                      |  | Code                           | V | Amount  | (A) or (D) | Price     |   |  |   |
| Common Stock                    | 12/04/2023                           |  | M                              |   | 15,000  | A          | \$3.29    | 37,771 <sup>(1)</sup>   | D  |   |
| Common Stock                    | 12/04/2023                           |  | F <sup>(2)</sup>               |   | 8,788   | D          | \$26.26   | 28,983 <sup>(1)</sup>   | D  |   |
| Common Stock                    | 12/05/2023                           |  | S                              |   | 1,381   | D          | \$26.2688 | 27,602 <sup>(1)</sup>   | D  |   |
| Common Stock                    | 12/06/2023                           |  | S                              |   | 6,212   | D          | \$27.01   | 21,390 <sup>(1)</sup>   | D  |   |
| Common Stock                    |                                      |  |                                |   |   |            |           | 8,061   | I  | Custodial Account for Child <sup>(3)</sup>            |
| Common Stock                    |                                      |  |                                |   |   |            |           | 8,061   | I  | Custodial Account for Child <sup>(3)</sup>            |
| Common Stock                    |                                      |  |                                |   |   |            |           | 8,061   | I  | Custodial Account for Child <sup>(3)</sup>            |

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) |   | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) |        | 6. Date Exercisable and Expiration Date (Month/Day/Year) |                 | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |       |
|--|--|--------------------------------------|--|--------------------------------|---|--|--------|--|-----------------|---|--|--|---|--|-------|
|  |  |                                      |  | Code                           | V | (A)  | (D)    | Date Exercisable   | Expiration Date |   |  |  |   |  | Title |
| Stock option (right to buy)                | \$3.29   | 12/04/2023                           |  | M                              |   |  | 15,000 | (4)  | 02/18/2025      | Common Stock  | 15,000                                     | \$0  | 61,037  | D  |       |

**Explanation of Responses:**

- Includes 1,600 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2023, 2,091 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023, and 500 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
- These shares were withheld so the Reporting Person could satisfy the exercise price and tax liability arising from a net (cashless) exercise of stock options that occurred on December 4, 2023. The options subject to the net exercise were to expire on February 18, 2025.
- These shares are held by a child of the Reporting Person through a custodial account under the Uniform Transfers to Minors Act for which the Reporting Person is custodian.
- Fully exercisable.

**Remarks:**

The power of attorney under which this form was signed is on file with the Commission.

/s/ Joseph Douglas Lyon, as attorney-in-fact for Gary Charles Robb 12/06/2023

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**